Standard BioTools Inc (LAB) Stock Price Prediction

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 818 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The firm works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. The company offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.